CompletedPhase 2ACTRN12608000016336

Ascorbate Supplementation in Kidney Failure

Ascorbate supplementation in Kidney failure and effect on quality of life


Sponsor

The Canberra Hospital

Enrollment

100 participants

Start Date

Jun 1, 2008

Study Type

Interventional

Conditions

Summary

The primary aim of this study is to discover if giving patients with severe kidney failure ascorbate (vitamin C) reduces symptoms that are common to both renal failure and ascorbate deficiency. It is known that low ascorbate levels are common in patients with severe kidney failure, and that symptoms of scurvy (ascorbate deficiency) and of kidney failure (uraemic syndrome) overlap. There is however no consensus on whether ascorbate supplementation is beneficial in patients with severe kidney disease and there are concerns that supplementation may cause adverse effects. This study would significantly improve clinical care, by examining the benefits and adverse outcomes of supplementation.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria1

  • Receiving maintenance dialysis treatment OR estimated Modification of Diet in Renal Diseases Glomerular Filtration Rate (MDRD GFR) of less than 20ml/min

Exclusion Criteria6

  • Life expectancy less than 3 months
  • Primary hyperoxaluria
  • Clinically unstable
  • Unable to provide informed consent
  • Unwilling to cease non study ascorbate containing supplements
  • Not fluent in English

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Oral ascorbic acid 250mg three times a week for 3 months from when subject is first enrolled into the study

Oral ascorbic acid 250mg three times a week for 3 months from when subject is first enrolled into the study


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000016336


Related Trials